Enlivex (ENLV) Operating Expenses (2013 - 2025)
Enlivex (ENLV) posted quarterly Operating Expenses of $5.9 million for Q4 2025, up 4.07% year-over-year from $5.6 million in Q4 2024, and up 129.21% quarter-over-quarter from $2.6 million in Q3 2025.
Enlivex (ENLV) Operating Expenses (2013 - 2025) Analysis & Trends
Enlivex's Operating Expenses history runs 13 years deep, the most recent figure standing at $5.9 million for Q4 2025.
- In Q4 2025, Operating Expenses rose 4.07% year-over-year to $5.9 million; the TTM figure through Dec 2025 stood at $15.0 million (down 5.41% YoY), while the FY2025 annual figure was $15.0 million, down 5.41% from the prior year.
- Operating Expenses for Q4 2025 stood at $5.9 million, up from $2.6 million in the prior quarter.
- The five-year high for Operating Expenses was $10.3 million in Q4 2023, with the low at $2.6 million in Q3 2025.
- The 5-year median for Operating Expenses is $5.6 million (2023), against an average of $5.3 million.
- The sharpest annual moves came in 2021 and 2024: Operating Expenses soared 111.36% in 2021, then tumbled 55.09% in 2024.
- Enlivex's Operating Expenses stood at $7.8 million in 2021, then gained by 0.4% to $7.8 million in 2022, then soared by 31.74% to $10.3 million in 2023, then tumbled by 45.51% to $5.6 million in 2024, then increased by 4.07% to $5.9 million in 2025.
- Business Quant data shows ENLV's Operating Expenses at $5.9 million in Q4 2025, $2.6 million in Q3 2025, and $3.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Enlivex | 4.58 Mn | -1.17 Mn | - | 5.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.86 Mn |
| Sep 30, 2025 | 2.56 Mn |
| Jun 30, 2025 | 3.08 Mn |
| Mar 31, 2025 | 3.53 Mn |
| Dec 31, 2024 | 5.63 Mn |
| Sep 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Mar 31, 2024 | 4.15 Mn |
| Dec 31, 2023 | 10.34 Mn |
| Sep 30, 2023 | 5.63 Mn |
| Jun 30, 2023 | 6.65 Mn |
| Mar 31, 2023 | 6.78 Mn |
| Dec 31, 2022 | 7.85 Mn |
| Sep 30, 2022 | 5.68 Mn |
| Jun 30, 2022 | 5.87 Mn |
| Mar 31, 2022 | 6.40 Mn |
| Dec 31, 2021 | 7.81 Mn |
| Sep 30, 2021 | 3.86 Mn |
| Jun 30, 2021 | 3.81 Mn |
| Mar 31, 2021 | 3.80 Mn |